Global Hepatocellular Carcinoma Treatment Market - 2025-2033
Global Hepatocellular Carcinoma Treatment Market – Trends & Overview
The global hepatocellular carcinoma treatment market size reached US$ 995.63 million in 2024 and is expected to reach US$ 1,964.88 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.
Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, originating from the liver’s primary cells known as hepatocytes. Management strategies for HCC depend on the cancer’s stage, the patient’s overall health, and additional clinical factors. Treatment options may include surgical resection, liver transplantation, local ablation techniques, chemotherapy, immunotherapy, and targeted therapies.
Key industry trends include a pronounced shift toward immunotherapies, especially immune checkpoint inhibitors, due to their improved survival outcomes and reduced side effects compared to traditional chemotherapies. Combination therapies and precision medicine approaches are gaining traction, with ongoing research focusing on patient stratification and personalized treatments. The integration of artificial intelligence in diagnostics and treatment planning is also enhancing early detection and tailored therapy strategies.
Major drivers for market growth include increasing global prevalence of liver cancer, particularly due to chronic liver diseases, hepatitis B and C, and non-alcoholic fatty liver disease (NAFLD). Enhanced awareness and screening leading to earlier diagnosis and higher demand for effective treatments, and technological advancements in imaging, liquid biopsy, and AI-powered diagnostics
Opportunities lie in expanding access to innovative therapies in emerging markets, the development of novel immunotherapy and targeted drug combinations, and the growing focus on patient-centric, minimally invasive treatments.
Global Hepatocellular Carcinoma Treatment Market Dynamics: Drivers & Restraints
Rising Prevalence of Hepatocellular Carcinoma (HCC)
The global burden of hepatocellular carcinoma (HCC) is rising sharply, making it a major public health concern. HCC is the most common form of primary liver cancer, as per National Center for Biotechnology Information (NCBI) data in June 2023, accounting for approximately 90% of all liver cancer cases worldwide. The incidence of HCC is projected to surpass one million new cases annually by 2025, reflecting a steady increase in recent decades.
The incidence of hepatocellular carcinoma (HCC) is projected to rise steadily over the next 30 years, reflecting a growing global health challenge. According to the Global Cancer Observatory, HCC ranked as the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide in 2022, with incidence rates expected to increase further in both men and women.
In India, the Global Cancer Observatory reports a relatively low age-standardized incidence rate for HCC at 2.7 per 100,000 population. However, mortality rates are disproportionately high, with the Indian Council of Medical Research (ICMR) estimating HCC mortality at 6.8 per 100,000 population. Recent registry data also indicate that while incidence, prevalence, and mortality rates for HCC in India remain lower than global averages, these rates are rising, particularly in certain regions and among women. This trend underscores the urgent need for enhanced surveillance, prevention, and early detection strategies to address the increasing burden of HCC in both India and worldwide.
Lack of Effective Biomarkers
One of the most significant challenges restraining the growth and effectiveness of the global hepatocellular carcinoma (HCC) treatment market is the lack of reliable molecular biomarkers to guide therapy selection and predict treatment response. Currently, systemic therapies for advanced HCC often demonstrate limited efficacy, in part because clinicians are unable to accurately identify which patients are most likely to benefit from specific drugs.
While several potential biomarkers-such as PD-1, PD-L1, CD3, and CD8-have been explored for their predictive value in immunotherapy, their clinical utility remains inconsistent. For example, although positive PD-L1 expression is associated with a higher objective response rate (ORR) to PD-1/PD-L1 inhibitors in HCC, a substantial proportion of patients with high PD-L1 expression still do not respond to treatment, and some patients with low or negative PD-L1 expression do benefit.
This variability is further complicated by the dynamic and multifactorial regulation of PD-L1, which can be influenced by tumor-intrinsic factors and the tumor microenvironment, making it an unreliable standalone biomarker for clinical decision-making.
Global Hepatocellular Carcinoma Treatment Market - Epidemiology Analysis
The rising incidence of HCC presents significant challenges in the global healthcare landscape. As per DataM intelligence estimates, particularly as its incidence is expected to increase from an estimated 0.91 million prevalent cases in 2024 to 1.03 million by 2030. This trend highlights the growing need for effective interventions, particularly in regions where HCC cancer rates are more pronounced, such as in developing countries and among high-risk populations.
Early detection, better treatment options, and advancements in healthcare systems in developed countries have improved outcomes, but significant challenges remain in developing nations. Addressing these disparities and fostering innovation in treatment options will be crucial for managing the growing burden of HCC cancer globally.
Global Hepatocellular Carcinoma Treatment Market - Segment Analysis
The global hepatocellular carcinoma treatment market is segmented based on cancer type, treatment type, and region.
Treatment Type:
The targeted therapy segment was valued at US$ 8,002.72 million in 2024 and is estimated to reach US$ 17,124.58 million by 2033, growing at a CAGR of 7.8% during the forecast period from 2025-2033
Targeted therapy has revolutionized the treatment landscape for hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. These therapies are designed to interfere with specific molecular targets involved in tumor growth and progression, offering a more precise approach than conventional treatments.
HCC pathogenesis is often driven by aberrant signaling pathways, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (c-MET). Targeted therapies aim to inhibit these pathways, thereby impeding tumor angiogenesis, cell proliferation, and survival. By selectively blocking these molecular targets, targeted therapies can effectively suppress tumor growth with potentially fewer side effects than traditional chemotherapy.
Targeted therapies have significantly advanced the treatment of HCC, offering more personalized and effective options for patients. Ongoing research and clinical trials continue to expand the arsenal of targeted agents, potentially improving outcomes for individuals affected by this challenging disease.
Global Hepatocellular Carcinoma Treatment Market - Geographical Analysis
The North America hepatocellular carcinoma treatment market was valued at US$ 436.09 million in 2024 and is estimated to reach US$ 940.63 million by 2033, growing at a CAGR of 7.9% during the forecast period from 2025-2033
North America is projected to maintain a dominant position in the global hepatocellular carcinoma treatment market, driven by several key factors includes high incidence and mortality rates as per Journal of Clinical and Translational Hepatology data in January 2024, between 2001 and 2020, a total of 467,346 patients were diagnosed with hepatocellular carcinoma (HCC) in the United States, with women comprising 26.0% of these cases.
During this period, HCC incidence rates increased in both sexes among women, rates rose from 2.38 per 100,000 population in 2001 to 3.09 per 100,000 in 2020, and among men, from 7.32 to 9.82 per 100,000. Despite these increases, there was no significant difference in the rate of change between men and women. Despite recent projections for HCC remains a major health concern, contributing to substantial morbidity and mortality. This high incidence underscores the urgent need for effective treatment options and drives market demand.
North America's well-established healthcare infrastructure facilitates the rapid adoption of innovative treatments. The region boasts state-of-the-art medical facilities, a robust regulatory framework, and a high level of healthcare access, ensuring that patients receive timely and effective care. These factors contribute to the region's leading position in the hepatocellular carcinoma treatment market.
For instance, in April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The presence of major pharmaceutical companies and research institutions in North America accelerates the development of novel therapeutics. Ongoing research and clinical trials lead to the introduction of advanced treatment options, including targeted therapies and immunotherapies, enhancing patient outcomes and expanding market opportunities.
The Asia-Pacific hepatocellular carcinoma treatment market was valued at US$ 233.59 million in 2024 and is estimated to reach US$ 519.72 million by 2033, growing at a CAGR of 8.2% during the forecast period from 2025-2033
The Asia-Pacific hepatocellular carcinoma (HCC) treatment market is experiencing rapid growth, driven by several key factors, including the rising Incidence of liver cancer. Countries like China and Japan have some of the world’s highest rates of liver cancer, largely due to the prevalence of chronic hepatitis B and C infections.
Significant investments in R&D, especially in Japan, are leading to the development of innovative therapies and clinical trials. Japanese agencies, such as the Japan Agency for Medical Research and Development (AMED), are actively promoting immunotherapy research for HCC. There is a strong shift toward immunotherapy and targeted therapies, with immunotherapy now representing nearly half of the systemic treatment market share for unresectable HCC in the region.
The use of AI-assisted imaging, liquid biopsies, and biomarker-driven strategies is improving early detection and enabling tailored treatments, particularly in technologically advanced markets like Japan and South Korea.
Japan plays a critical role in this market due to its high disease burden, robust pharmaceutical industry, and leadership in clinical innovation. The Asia-Pacific HCC treatment market is forecasted to register a strong CAGR, with Japan remaining a key contributor to both market size and the advancement of new therapies.
Global Hepatocellular Carcinoma Treatment Market - Competitive Landscape (Major Players)
Top companies in the hepatocellular carcinoma treatment market include Eli Lilly and Company, AstraZeneca, Eisai Inc., TAIHO ONCOLOGY, INC., Bayer AG, Bristol-Myers Squibb Company., Incyte, Genentech USA, Inc., Exelixis, Inc., and Merck & Co., Inc., among others.
Global Hepatocellular Carcinoma Treatment Market - Competitive Landscape (Emerging Players)
Emerging players in the hepatocellular carcinoma treatment market include Oricell Therapeutics, Biosyngen, Abivax SA, SCG Cell Therapy Ptd Ltd, TCM Biotech International Corp., ITERION THERAPEUTICS, INC., Alnylam Pharmaceuticals, Inc., Shanghai Henlius Biotech, Inc., and Tvardi Therapeutics, Inc., among others.
Global Hepatocellular Carcinoma Treatment Market - Key Developments
The global hepatocellular carcinoma treatment market size reached US$ 995.63 million in 2024 and is expected to reach US$ 1,964.88 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.
Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, originating from the liver’s primary cells known as hepatocytes. Management strategies for HCC depend on the cancer’s stage, the patient’s overall health, and additional clinical factors. Treatment options may include surgical resection, liver transplantation, local ablation techniques, chemotherapy, immunotherapy, and targeted therapies.
Key industry trends include a pronounced shift toward immunotherapies, especially immune checkpoint inhibitors, due to their improved survival outcomes and reduced side effects compared to traditional chemotherapies. Combination therapies and precision medicine approaches are gaining traction, with ongoing research focusing on patient stratification and personalized treatments. The integration of artificial intelligence in diagnostics and treatment planning is also enhancing early detection and tailored therapy strategies.
Major drivers for market growth include increasing global prevalence of liver cancer, particularly due to chronic liver diseases, hepatitis B and C, and non-alcoholic fatty liver disease (NAFLD). Enhanced awareness and screening leading to earlier diagnosis and higher demand for effective treatments, and technological advancements in imaging, liquid biopsy, and AI-powered diagnostics
Opportunities lie in expanding access to innovative therapies in emerging markets, the development of novel immunotherapy and targeted drug combinations, and the growing focus on patient-centric, minimally invasive treatments.
Global Hepatocellular Carcinoma Treatment Market Dynamics: Drivers & Restraints
Rising Prevalence of Hepatocellular Carcinoma (HCC)
The global burden of hepatocellular carcinoma (HCC) is rising sharply, making it a major public health concern. HCC is the most common form of primary liver cancer, as per National Center for Biotechnology Information (NCBI) data in June 2023, accounting for approximately 90% of all liver cancer cases worldwide. The incidence of HCC is projected to surpass one million new cases annually by 2025, reflecting a steady increase in recent decades.
The incidence of hepatocellular carcinoma (HCC) is projected to rise steadily over the next 30 years, reflecting a growing global health challenge. According to the Global Cancer Observatory, HCC ranked as the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide in 2022, with incidence rates expected to increase further in both men and women.
In India, the Global Cancer Observatory reports a relatively low age-standardized incidence rate for HCC at 2.7 per 100,000 population. However, mortality rates are disproportionately high, with the Indian Council of Medical Research (ICMR) estimating HCC mortality at 6.8 per 100,000 population. Recent registry data also indicate that while incidence, prevalence, and mortality rates for HCC in India remain lower than global averages, these rates are rising, particularly in certain regions and among women. This trend underscores the urgent need for enhanced surveillance, prevention, and early detection strategies to address the increasing burden of HCC in both India and worldwide.
Lack of Effective Biomarkers
One of the most significant challenges restraining the growth and effectiveness of the global hepatocellular carcinoma (HCC) treatment market is the lack of reliable molecular biomarkers to guide therapy selection and predict treatment response. Currently, systemic therapies for advanced HCC often demonstrate limited efficacy, in part because clinicians are unable to accurately identify which patients are most likely to benefit from specific drugs.
While several potential biomarkers-such as PD-1, PD-L1, CD3, and CD8-have been explored for their predictive value in immunotherapy, their clinical utility remains inconsistent. For example, although positive PD-L1 expression is associated with a higher objective response rate (ORR) to PD-1/PD-L1 inhibitors in HCC, a substantial proportion of patients with high PD-L1 expression still do not respond to treatment, and some patients with low or negative PD-L1 expression do benefit.
This variability is further complicated by the dynamic and multifactorial regulation of PD-L1, which can be influenced by tumor-intrinsic factors and the tumor microenvironment, making it an unreliable standalone biomarker for clinical decision-making.
Global Hepatocellular Carcinoma Treatment Market - Epidemiology Analysis
The rising incidence of HCC presents significant challenges in the global healthcare landscape. As per DataM intelligence estimates, particularly as its incidence is expected to increase from an estimated 0.91 million prevalent cases in 2024 to 1.03 million by 2030. This trend highlights the growing need for effective interventions, particularly in regions where HCC cancer rates are more pronounced, such as in developing countries and among high-risk populations.
Early detection, better treatment options, and advancements in healthcare systems in developed countries have improved outcomes, but significant challenges remain in developing nations. Addressing these disparities and fostering innovation in treatment options will be crucial for managing the growing burden of HCC cancer globally.
Global Hepatocellular Carcinoma Treatment Market - Segment Analysis
The global hepatocellular carcinoma treatment market is segmented based on cancer type, treatment type, and region.
Treatment Type:
The targeted therapy segment was valued at US$ 8,002.72 million in 2024 and is estimated to reach US$ 17,124.58 million by 2033, growing at a CAGR of 7.8% during the forecast period from 2025-2033
Targeted therapy has revolutionized the treatment landscape for hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. These therapies are designed to interfere with specific molecular targets involved in tumor growth and progression, offering a more precise approach than conventional treatments.
HCC pathogenesis is often driven by aberrant signaling pathways, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (c-MET). Targeted therapies aim to inhibit these pathways, thereby impeding tumor angiogenesis, cell proliferation, and survival. By selectively blocking these molecular targets, targeted therapies can effectively suppress tumor growth with potentially fewer side effects than traditional chemotherapy.
Targeted therapies have significantly advanced the treatment of HCC, offering more personalized and effective options for patients. Ongoing research and clinical trials continue to expand the arsenal of targeted agents, potentially improving outcomes for individuals affected by this challenging disease.
Global Hepatocellular Carcinoma Treatment Market - Geographical Analysis
The North America hepatocellular carcinoma treatment market was valued at US$ 436.09 million in 2024 and is estimated to reach US$ 940.63 million by 2033, growing at a CAGR of 7.9% during the forecast period from 2025-2033
North America is projected to maintain a dominant position in the global hepatocellular carcinoma treatment market, driven by several key factors includes high incidence and mortality rates as per Journal of Clinical and Translational Hepatology data in January 2024, between 2001 and 2020, a total of 467,346 patients were diagnosed with hepatocellular carcinoma (HCC) in the United States, with women comprising 26.0% of these cases.
During this period, HCC incidence rates increased in both sexes among women, rates rose from 2.38 per 100,000 population in 2001 to 3.09 per 100,000 in 2020, and among men, from 7.32 to 9.82 per 100,000. Despite these increases, there was no significant difference in the rate of change between men and women. Despite recent projections for HCC remains a major health concern, contributing to substantial morbidity and mortality. This high incidence underscores the urgent need for effective treatment options and drives market demand.
North America's well-established healthcare infrastructure facilitates the rapid adoption of innovative treatments. The region boasts state-of-the-art medical facilities, a robust regulatory framework, and a high level of healthcare access, ensuring that patients receive timely and effective care. These factors contribute to the region's leading position in the hepatocellular carcinoma treatment market.
For instance, in April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The presence of major pharmaceutical companies and research institutions in North America accelerates the development of novel therapeutics. Ongoing research and clinical trials lead to the introduction of advanced treatment options, including targeted therapies and immunotherapies, enhancing patient outcomes and expanding market opportunities.
The Asia-Pacific hepatocellular carcinoma treatment market was valued at US$ 233.59 million in 2024 and is estimated to reach US$ 519.72 million by 2033, growing at a CAGR of 8.2% during the forecast period from 2025-2033
The Asia-Pacific hepatocellular carcinoma (HCC) treatment market is experiencing rapid growth, driven by several key factors, including the rising Incidence of liver cancer. Countries like China and Japan have some of the world’s highest rates of liver cancer, largely due to the prevalence of chronic hepatitis B and C infections.
Significant investments in R&D, especially in Japan, are leading to the development of innovative therapies and clinical trials. Japanese agencies, such as the Japan Agency for Medical Research and Development (AMED), are actively promoting immunotherapy research for HCC. There is a strong shift toward immunotherapy and targeted therapies, with immunotherapy now representing nearly half of the systemic treatment market share for unresectable HCC in the region.
The use of AI-assisted imaging, liquid biopsies, and biomarker-driven strategies is improving early detection and enabling tailored treatments, particularly in technologically advanced markets like Japan and South Korea.
Japan plays a critical role in this market due to its high disease burden, robust pharmaceutical industry, and leadership in clinical innovation. The Asia-Pacific HCC treatment market is forecasted to register a strong CAGR, with Japan remaining a key contributor to both market size and the advancement of new therapies.
Global Hepatocellular Carcinoma Treatment Market - Competitive Landscape (Major Players)
Top companies in the hepatocellular carcinoma treatment market include Eli Lilly and Company, AstraZeneca, Eisai Inc., TAIHO ONCOLOGY, INC., Bayer AG, Bristol-Myers Squibb Company., Incyte, Genentech USA, Inc., Exelixis, Inc., and Merck & Co., Inc., among others.
Global Hepatocellular Carcinoma Treatment Market - Competitive Landscape (Emerging Players)
Emerging players in the hepatocellular carcinoma treatment market include Oricell Therapeutics, Biosyngen, Abivax SA, SCG Cell Therapy Ptd Ltd, TCM Biotech International Corp., ITERION THERAPEUTICS, INC., Alnylam Pharmaceuticals, Inc., Shanghai Henlius Biotech, Inc., and Tvardi Therapeutics, Inc., among others.
Global Hepatocellular Carcinoma Treatment Market - Key Developments
- In April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- In February 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BST02, an investigational T-cell therapy developed by Biosyngen, for the treatment of all forms of liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma. This designation aims to expedite the development and review processes for therapies addressing serious conditions with unmet medical needs.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Hepatocellular Carcinoma (HCC)
3.1.1.2. Rising Demand for Combination Therapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Effective Biomarkers
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Growth of Artificial Intelligence and Machine Learning Models
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Fibrolamellar HCC*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Sarcomatoid HCC
6. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Immunotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Nivolumab
6.2.4. Bevacizumab
6.2.5. Pembrolizumab
6.2.6. Atezolizumab
6.2.7. Others
6.3. Targeted therapy
6.3.1. Sorafenib
6.3.2. Lenvatinib
6.3.3. Cabozantinib
6.3.4. Regorafenib
6.3.5. Others
6.4. Radiation Therapy
6.5. Ablation and Embolization Therapies
6.6. Surgery
6.7. Others
7. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Key Players
9.1. Eli Lilly and Company
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AstraZeneca
9.3. Eisai Inc.
9.4. TAIHO ONCOLOGY, INC.
9.5. Bayer AG
9.6. Bristol-Myers Squibb Company.
9.7. Incyte.
9.8. Genentech USA, Inc.
9.9. Exelixis, Inc.
9.10. Merck & Co., Inc.
Emerging Players
9.11. Oricell Therapeutics
9.12. Biosyngen
9.13. Abivax SA
9.14. SCG Cell Therapy Ptd Ltd
9.15. TCM Biotech International Corp.
9.16. ITERION THERAPEUTICS, INC
9.17. Alnylam Pharmaceuticals, Inc.
9.18. Shanghai Henlius Biotech, Inc.
9.19. Tvardi Therapeutics, Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Hepatocellular Carcinoma (HCC)
3.1.1.2. Rising Demand for Combination Therapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Effective Biomarkers
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Growth of Artificial Intelligence and Machine Learning Models
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Fibrolamellar HCC*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Sarcomatoid HCC
6. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Immunotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Nivolumab
6.2.4. Bevacizumab
6.2.5. Pembrolizumab
6.2.6. Atezolizumab
6.2.7. Others
6.3. Targeted therapy
6.3.1. Sorafenib
6.3.2. Lenvatinib
6.3.3. Cabozantinib
6.3.4. Regorafenib
6.3.5. Others
6.4. Radiation Therapy
6.5. Ablation and Embolization Therapies
6.6. Surgery
6.7. Others
7. HEPATOCELLULAR CARCINOMA TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Key Players
9.1. Eli Lilly and Company
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AstraZeneca
9.3. Eisai Inc.
9.4. TAIHO ONCOLOGY, INC.
9.5. Bayer AG
9.6. Bristol-Myers Squibb Company.
9.7. Incyte.
9.8. Genentech USA, Inc.
9.9. Exelixis, Inc.
9.10. Merck & Co., Inc.
Emerging Players
9.11. Oricell Therapeutics
9.12. Biosyngen
9.13. Abivax SA
9.14. SCG Cell Therapy Ptd Ltd
9.15. TCM Biotech International Corp.
9.16. ITERION THERAPEUTICS, INC
9.17. Alnylam Pharmaceuticals, Inc.
9.18. Shanghai Henlius Biotech, Inc.
9.19. Tvardi Therapeutics, Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 10 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 12 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 14 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 18 North America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 19 North America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 20 North America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 South America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 23 South America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 24 South America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 25 South America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 28 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 29 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 30 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Merck & Co., Inc.: Overview
Table 42 Merck & Co., Inc.: Product Portfolio
Table 43 Merck & Co., Inc.: Key Developments
Table 44 GSK plc.: Overview
Table 45 GSK plc.: Product Portfolio
Table 46 GSK plc.: Key Developments
Table 47 Wantai BioPharm.: Overview
Table 48 Wantai BioPharm.: Product Portfolio
Table 49 Wantai BioPharm.: Key Developments
Table 50 Walvax Biotechnology Co., Ltd.: Overview
Table 51 Walvax Biotechnology Co., Ltd.: Product Portfolio
Table 52 Walvax Biotechnology Co., Ltd.: Key Developments
Table 53 Serum Institute of India Pvt. Ltd.: Overview
Table 54 Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 55 Serum Institute of India Pvt. Ltd.: Key Developments
Table 56 DCVMN International.: Overview
Table 57 DCVMN International.: Product Portfolio
Table 58 DCVMN International.: Key Developments
Table 59 Shanghai Zerun Biotech Co., Ltd.: Overview
Table 60 Shanghai Zerun Biotech Co., Ltd.: Product Portfolio
Table 61 Shanghai Zerun Biotech Co., Ltd.: Key Developments
Table 62 Shanghai Bovax Biotechnology Co., Ltd.: Overview
Table 63 Shanghai Bovax Biotechnology Co., Ltd.: Product Portfolio
Table 64 Shanghai Bovax Biotechnology Co., Ltd.: Key Developments
Table 65 Jiangsu Recbio Technology Co., Ltd.: Overview
Table 66 Jiangsu Recbio Technology Co., Ltd.: Product Portfolio
Table 67 Jiangsu Recbio Technology Co., Ltd.: Key Developments
Table 68 Oricell Therapeutics: Overview
Table 69 Oricell Therapeutics: Product Portfolio
Table 70 Oricell Therapeutics: Key Developments
Table 71 Biosyngen: Overview
Table 72 Biosyngen: Product Portfolio
Table 73 Biosyngen: Key Developments
Table 74 Abivax SA: Overview
Table 75 Abivax SA: Product Portfolio
Table 76 Abivax SA: Key Developments
Table 77 SCG Cell Therapy Ptd Ltd: Overview
Table 78 SCG Cell Therapy Ptd Ltd: Product Portfolio
Table 79 SCG Cell Therapy Ptd Ltd: Key Developments
Table 80 TCM Biotech International Corp.: Overview
Table 81 TCM Biotech International Corp.: Product Portfolio
Table 82 TCM Biotech International Corp.: Key Developments
Table 83 ITERION THERAPEUTICS, INC: Overview
Table 84 ITERION THERAPEUTICS, INC: Product Portfolio
Table 85 ITERION THERAPEUTICS, INC: Key Developments
Table 86 Alnylam Pharmaceuticals, Inc.: Overview
Table 87 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 88 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 89 Shanghai Henlius Biotech, Inc.: Overview
Table 90 Shanghai Henlius Biotech, Inc.: Product Portfolio
Table 91 Shanghai Henlius Biotech, Inc.: Key Developments
Table 92 Tvardi Therapeutics, Inc.: Overview
Table 93 Tvardi Therapeutics, Inc.: Product Portfolio
Table 94 Tvardi Therapeutics, Inc.: Key Developments
Table 1 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 10 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 12 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 14 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 18 North America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 19 North America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 20 North America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 South America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 23 South America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 24 South America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 25 South America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 28 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 29 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 30 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Merck & Co., Inc.: Overview
Table 42 Merck & Co., Inc.: Product Portfolio
Table 43 Merck & Co., Inc.: Key Developments
Table 44 GSK plc.: Overview
Table 45 GSK plc.: Product Portfolio
Table 46 GSK plc.: Key Developments
Table 47 Wantai BioPharm.: Overview
Table 48 Wantai BioPharm.: Product Portfolio
Table 49 Wantai BioPharm.: Key Developments
Table 50 Walvax Biotechnology Co., Ltd.: Overview
Table 51 Walvax Biotechnology Co., Ltd.: Product Portfolio
Table 52 Walvax Biotechnology Co., Ltd.: Key Developments
Table 53 Serum Institute of India Pvt. Ltd.: Overview
Table 54 Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 55 Serum Institute of India Pvt. Ltd.: Key Developments
Table 56 DCVMN International.: Overview
Table 57 DCVMN International.: Product Portfolio
Table 58 DCVMN International.: Key Developments
Table 59 Shanghai Zerun Biotech Co., Ltd.: Overview
Table 60 Shanghai Zerun Biotech Co., Ltd.: Product Portfolio
Table 61 Shanghai Zerun Biotech Co., Ltd.: Key Developments
Table 62 Shanghai Bovax Biotechnology Co., Ltd.: Overview
Table 63 Shanghai Bovax Biotechnology Co., Ltd.: Product Portfolio
Table 64 Shanghai Bovax Biotechnology Co., Ltd.: Key Developments
Table 65 Jiangsu Recbio Technology Co., Ltd.: Overview
Table 66 Jiangsu Recbio Technology Co., Ltd.: Product Portfolio
Table 67 Jiangsu Recbio Technology Co., Ltd.: Key Developments
Table 68 Oricell Therapeutics: Overview
Table 69 Oricell Therapeutics: Product Portfolio
Table 70 Oricell Therapeutics: Key Developments
Table 71 Biosyngen: Overview
Table 72 Biosyngen: Product Portfolio
Table 73 Biosyngen: Key Developments
Table 74 Abivax SA: Overview
Table 75 Abivax SA: Product Portfolio
Table 76 Abivax SA: Key Developments
Table 77 SCG Cell Therapy Ptd Ltd: Overview
Table 78 SCG Cell Therapy Ptd Ltd: Product Portfolio
Table 79 SCG Cell Therapy Ptd Ltd: Key Developments
Table 80 TCM Biotech International Corp.: Overview
Table 81 TCM Biotech International Corp.: Product Portfolio
Table 82 TCM Biotech International Corp.: Key Developments
Table 83 ITERION THERAPEUTICS, INC: Overview
Table 84 ITERION THERAPEUTICS, INC: Product Portfolio
Table 85 ITERION THERAPEUTICS, INC: Key Developments
Table 86 Alnylam Pharmaceuticals, Inc.: Overview
Table 87 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 88 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 89 Shanghai Henlius Biotech, Inc.: Overview
Table 90 Shanghai Henlius Biotech, Inc.: Product Portfolio
Table 91 Shanghai Henlius Biotech, Inc.: Key Developments
Table 92 Tvardi Therapeutics, Inc.: Overview
Table 93 Tvardi Therapeutics, Inc.: Product Portfolio
Table 94 Tvardi Therapeutics, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 4 Global Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 5 Global Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Human Papillomavirus (HPV) Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Fibrolamellar HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 9 Sarcomatoid HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Gender, 2023-2033 (%)
Figure 11 Female Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 12 Male Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Age Group, 2023-2033 (%)
Figure 14 Children Age Group in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 15 Adults Age Group in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 17 Cervical Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 18 Vaginal Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Anal Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Others Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 24 North America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 25 North America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 26 North America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 27 North America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 28 South America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 29 South America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 30 South America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 31 South America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 32 South America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 33 South America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 34 Europe Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 35 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 36 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 38 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 40 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 41 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 42 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 43 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 44 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 45 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 49 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 50 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 51 Merck & Co., Inc.: Financials
Figure 52 GSK plc.: Financials
Figure 53 Wantai BioPharm.: Financials
Figure 54 Walvax Biotechnology Co., Ltd.: Financials
Figure 55 Serum Institute of India Pvt. Ltd.: Financials
Figure 56 DCVMN International.: Financials
Figure 57 Shanghai Zerun Biotech Co., Ltd.: Financials
Figure 58 Shanghai Bovax Biotechnology Co., Ltd.: Financials
Figure 59 Jiangsu Recbio Technology Co., Ltd.: Financials
Figure 60 Oricell Therapeutics: Financials
Figure 61 Biosyngen: Financials
Figure 62 Abivax SA: Financials
Figure 63 SCG Cell Therapy Ptd Ltd: Financials
Figure 64 TCM Biotech International Corp.: Financials
Figure 65 ITERION THERAPEUTICS, INC: Financials
Figure 66 Alnylam Pharmaceuticals, Inc.: Financials
Figure 67 Shanghai Henlius Biotech, Inc.: Financials
Figure 68 Tvardi Therapeutics, Inc.: Financials
Figure 1 Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 4 Global Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 5 Global Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Human Papillomavirus (HPV) Vaccines Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Fibrolamellar HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 9 Sarcomatoid HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Gender, 2023-2033 (%)
Figure 11 Female Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 12 Male Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Age Group, 2023-2033 (%)
Figure 14 Children Age Group in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 15 Adults Age Group in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 17 Cervical Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 18 Vaginal Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 19 Anal Cancer Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 20 Others Indication in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 24 North America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 25 North America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 26 North America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 27 North America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 28 South America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 29 South America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 30 South America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 31 South America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 32 South America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 33 South America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 34 Europe Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 35 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 36 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 38 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 39 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 40 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 41 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 42 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 43 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 44 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 45 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)
Figure 48 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)
Figure 49 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)
Figure 50 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)
Figure 51 Merck & Co., Inc.: Financials
Figure 52 GSK plc.: Financials
Figure 53 Wantai BioPharm.: Financials
Figure 54 Walvax Biotechnology Co., Ltd.: Financials
Figure 55 Serum Institute of India Pvt. Ltd.: Financials
Figure 56 DCVMN International.: Financials
Figure 57 Shanghai Zerun Biotech Co., Ltd.: Financials
Figure 58 Shanghai Bovax Biotechnology Co., Ltd.: Financials
Figure 59 Jiangsu Recbio Technology Co., Ltd.: Financials
Figure 60 Oricell Therapeutics: Financials
Figure 61 Biosyngen: Financials
Figure 62 Abivax SA: Financials
Figure 63 SCG Cell Therapy Ptd Ltd: Financials
Figure 64 TCM Biotech International Corp.: Financials
Figure 65 ITERION THERAPEUTICS, INC: Financials
Figure 66 Alnylam Pharmaceuticals, Inc.: Financials
Figure 67 Shanghai Henlius Biotech, Inc.: Financials
Figure 68 Tvardi Therapeutics, Inc.: Financials
